Gefitinib is an anticancer drug for certain breast, lung and other cancers. It is an epidermal growth factor receptor (EGFR) inhibitor. Researchers found that nonfunctional EGFR dimmers can be formed by gefitinib but the exact molecular mechanism needs further study. So, it could be one of the points of your research in cancer therapy as the identification of this mechanism could open new doors of treatment and prognosis.
Receptor tyrosine kinases of the EGFR family are found to be overly expressed in solid tumors. EGFR is involved in many cellular functions such as proliferation, differentiation and survival. They could be the potential targets in cancer therapies. So, you can work on different ways to target these proteins such as radiotherapy, chemotherapy, gene therapy, immunotherapy or combination of these.
You can also work on these proteins and find ways to consider them as biomarkers for the diagnosis of cancer. Moreover, the presence of other diseases which are related to elevated levels of these proteins.
He P, & Li G (2013). Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib. Cancer chemotherapy and pharmacology, 72 (2), 341-8 PMID: 23748900